Syndax appoints Steven Closter as CCO as Steve Sabus resigns; expects two product launches in 2024

Syndax Pharmaceuticals Inc

Steve Sabus voluntarily resigned as CCO on March 15, 2024 due to personal reasons.
Steven Closter appointed CCO effective March 18; leads commercial strategy for anticipated launches of revumenib and axatilimab.
Closter received base salary $460K, 45% target bonus, option for 150K shares, PRSU of 25K units, and sign-on RSU of 9K units.
Closter brings over 30 years biopharma commercial experience, previously VP at Sunovion/Sumitomo Pharma America and Forest Labs/Allergan.
Company reaffirms on track for two first- and best-in-class product launches in 2024.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Steven Closter

Chief Commercial Officer

SNDX · Syndax Pharmaceuticals Inc

Effective: 2024-03-18
Filed: March 18, 2024, 7:59 PM ET

On March 18, 2024, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Steven Closter will join the Company as Chief Commercial Officer, effective immediately.

Departed

Steve Sabus

Chief Commercial Officer

SNDX · Syndax Pharmaceuticals Inc

Effective: 2024-03-15
Successor: Steven Closter
Filed: March 18, 2024, 7:59 PM ET

On March 15, 2024, Steve Sabus, the previous Chief Commercial Officer of the Company, notified the Company of his voluntary resignation from his position due to personal reasons.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Steven Closter was appointed as Chief Commercial Officer at Syndax Pharmaceuticals Inc.

Action: appointed
Role: Chief Commercial Officer

Exact text from the filing

On March 18, 2024, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Steven Closter will join the Company as Chief Commercial Officer, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Steve Sabus resigned as Chief Commercial Officer at Syndax Pharmaceuticals Inc.

Action: resigned
Role: Chief Commercial Officer

Exact text from the filing

On March 15, 2024, Steve Sabus, the previous Chief Commercial Officer of the Company, notified the Company of his voluntary resignation from his position due to personal reasons.

View on SEC.gov

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0000950170-24-032514

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.